Moderna mRNA - Search News

Agrees to review Moderna flu vaccine

FDA reverses course, will review Moderna's mRNA flu vaccine

Moderna said on Wednesday the U.S. Food and Drug Administration has agreed to review its influenza vaccine, reversing an earlier decision to reject the application, after the company made modification...

· 1d · on MSN

FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal

Straight Arrow News (English) on MSN · 1d

FDA to review Moderna's mRNA flu vaccine after initial rejection

· 1d

FDA Reverses Course, Will Review Moderna's mRNA Flu Vaccine

Moderna said the U.S. Food and Drug Administration has agreed to review its influenza vaccine, reversing an earlier decision to reject the application.

· 20h

FDA reverses course on Moderna's flu vaccine

Scientific American · 1d

FDA agrees to review Moderna mRNA flu vaccine in dramatic reversal

· 1d

FDA Reverses Course and Will Now Review Moderna’s Flu Shot

The move means that Moderna’s experimental flu shot is largely back on track after the FDA’s surprise decision earlier this month to refuse to start a review of its application.

Axios · 1d

FDA will now review flu vaccine it had rejected

· 1d

US FDA reverses course, will review Moderna's flu vaccine application

BioSpace

Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.

Just The News

Moderna threatens American jobs after FDA snubs mRNA flu shot, trial looked 'scientifically lax'

Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by White House.

Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico

Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA

Opinion

BioSpaceOpinion

Moderna’s mRNA Vaccine Refusal Comes Amid Global Advanced Therapies Push

The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is “part of a disturbing pattern” of moving regulatory goalposts, according to Clay Alspach, executive director of the Alliance for mRNA Medicines.

Blockonomi

Moderna (MRNA) Stock Slips Despite Beating Q4 Revenue and Earnings Estimates

Moderna (MRNA) stock fell 0.3% Friday despite beating Q4 revenue estimates at $678M and posting narrower loss of $2.11/share after FDA rejected flu vaccine review.